Ovid Therapeutics reduces headcount by 43%
PremiumThe FlyOvid Therapeutics reduces headcount by 43%
3M ago
Ovid Therapeutics reports cash position of $77M as of June 30
Premium
The Fly
Ovid Therapeutics reports cash position of $77M as of June 30
3M ago
Ovid Therapeutics reports Q2 EPS 12c, consensus (22c)
Premium
The Fly
Ovid Therapeutics reports Q2 EPS 12c, consensus (22c)
3M ago
Ovid Therapeutics announces eNeuro published studies on OV329 mechanism
PremiumThe FlyOvid Therapeutics announces eNeuro published studies on OV329 mechanism
4M ago
Ovid Therapeutics, Graviton announce data from trial of OV888/GV101 capsule
Premium
The Fly
Ovid Therapeutics, Graviton announce data from trial of OV888/GV101 capsule
4M ago
Ovid Therapeutics Announces Workforce Reduction to Extend Runway
Premium
Company Announcements
Ovid Therapeutics Announces Workforce Reduction to Extend Runway
5M ago
Oppenheimer downgrades Ovid Therapeutics to Perform following Soticlestat misses
PremiumThe FlyOppenheimer downgrades Ovid Therapeutics to Perform following Soticlestat misses
5M ago
Ovid Therapeutics price target lowered to $2 from $7 at Ladenburg
Premium
The Fly
Ovid Therapeutics price target lowered to $2 from $7 at Ladenburg
5M ago
Ovid Therapeutics downgraded to Perform from Outperform at Oppenheimer
Premium
The Fly
Ovid Therapeutics downgraded to Perform from Outperform at Oppenheimer
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100